This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
J&J to Appeal as Judge Confirms Jury Order in Talc Case
by Zacks Equity Research
Johnson & Johnson's (JNJ) suffers setback as Missouri judge confirms talc lawsuit jury verdict. The company intends to appeal against the decision.
Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio
by Kinjel Shah
The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.
Allergan Falls on FDA's Rejection of Uterine Fibroids Drug
by Zacks Equity Research
FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.
Infinity Focuses on Developing IPI-549 for Solid Tumors
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.
Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition
by Zacks Equity Research
Horizon Pharma (HZNP) remains focused on advancing its pipeline candidates and is also making efforts to expand the label of its already approved drugs.
Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.
Roche's Lung Cancer Drug Alecensa Gets Approval in China
by Zacks Equity Research
The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Bristol-Myers Squibb (BMY) a Great Dividend Play?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
5 Top-Ranked S&P 500 Stocks to Buy on Market Dip
by Tirthankar Chakraborty
As the long term picture is rosy after the initial dip, it will be wise to invest in growth stocks. Also, stocks after a dip are at a discount.
Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf
by Zacks Equity Research
Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf
Pick These 5 Stocks With Remarkable Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Intrexon Reports Preliminary Earnings and Revenues for Q2
by Zacks Equity Research
Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
by Zacks Equity Research
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.
Q2 Earnings Drive Pharma ETFs Higher
by Sweta Killa
The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.
BMY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval
by Zacks Equity Research
Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) misses bottom-line estimates in the second quarter but beats on the top line. Rubraca sales increase.
Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?
by Zacks Equity Research
Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.
Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2
by Zacks Equity Research
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.